441 related articles for article (PubMed ID: 25933207)
1. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
2. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
6. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.
Merrill SP; Reynolds P; Kalra A; Biehl J; Vandivier RW; Mueller SW
Ann Pharmacother; 2014 Jun; 48(6):806-10. PubMed ID: 24651165
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
9. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
Beniwal-Patel P; Matkowskyj K; Caldera F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
[No Abstract] [Full Text] [Related]
10. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
12. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab-induced perforating colitis.
Mitchell KA; Kluger H; Sznol M; Hartman DJ
J Clin Gastroenterol; 2013 Oct; 47(9):781-5. PubMed ID: 23632354
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.
Klair JS; Girotra M; Hutchins LF; Caradine KD; Aduli F; Garcia-Saenz-de-Sicilia M
Dig Dis Sci; 2016 Jul; 61(7):2132-9. PubMed ID: 26846115
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Johnson DB; Sullivan RJ; Ott PA; Carlino MS; Khushalani NI; Ye F; Guminski A; Puzanov I; Lawrence DP; Buchbinder EI; Mudigonda T; Spencer K; Bender C; Lee J; Kaufman HL; Menzies AM; Hassel JC; Mehnert JM; Sosman JA; Long GV; Clark JI
JAMA Oncol; 2016 Feb; 2(2):234-40. PubMed ID: 26633184
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for ipilimumab-induced colitis: A series of 13 patients.
Hillock NT; Heard S; Kichenadasse G; Hill CL; Andrews J
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e284-e290. PubMed ID: 27981760
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: colitis associated with anti-CTLA-4 therapy.
Gupta A; De Felice KM; Loftus EV; Khanna S
Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab: a novel treatment for ipilimumab-induced colitis.
Hsieh AH; Ferman M; Brown MP; Andrews JM
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539137
[TBL] [Abstract][Full Text] [Related]
20. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
